No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
PFE241227C26500
- 0.26
- +0.03+13.04%
15min DelayTrading Dec 23 09:30 ET
0.28High0.17Low
0.27Open0.23Pre Close45 Volume22.73K Open Interest26.50Strike Price1.10KTurnover21.13%IV1.30%PremiumDec 27, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.26Extrinsic Value100Contract SizeAmericanOptions Type0.3422Delta0.6132Gamma101.60Leverage Ratio-0.0282Theta0.0010Rho34.77Eff Leverage0.0104Vega
Intraday
- 5D
- Daily
No Data
News
Pfizer's Colorectal Cancer Combo Therapy Gains Accelerated Approval From FDA
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts